UPDATE Opioid Crisis – More Evidence Pointing to Overdose-Reversing Naloxone, Not Substitute Opioids, Reducing OD Deaths

by Clark Miller

January 2, 2019

As public health resources are increasingly diverted to a medical “fix” for a worsening, lethal opioid crisis, evidence continues to mount pointing away from beneficial effects attributable to substitute opioid (buprenorphine, methadone) programs instead to concurrently expanding use of Naloxone – the opioid antagonist administered acutely to reverse respiratory depression in life-threatening opioid overdoses – as the factor accounting, directly, for any apparent moderation of national or local decreases in overdose deaths.

naloxone

That is, the evidence, critically examined, says that the medical “fix” is not helping with high-risk opioid use or overdose rates, more likely worsening it, and the “evidence” for reduced OD deaths attributable to OST (MAT) used to market the medical/pharmaceutical/harm-reduction industry “treatment” doesn’t hold up, never has, instead points to Naloxone as the effective factor in slowing deaths. Meanwhile diversion and abuse fueled by a runaway national “dose” of substitute addictive opioids – as in generation of the crisis – is integral to national high-risk opioid use economies – diversion and abuse of addictive opioids driving a street and prison economy; diversion and abuse of public healthcare funds driving a supplier economy constructed as “medical treatment”.

shutterstock Suboxone

That mounting evidence has included –

Retention rates (patients staying in and successfully completing MAT treatment programs) low and trending to zero in natural community treatment settings, with concurrent misuse of other opioids, other drugs – described in this post:

Doxa Deconstructed: Another Medical Fix Not Supported by Evidence – Suboxone for the Opioid Crisis

Evidence in the anomalous case of a Plumas County, California reversing opioid-related OD deaths pointing to Naloxone as the effective protective factor and against OST – described in this post:

In a California county hard-hit by opioid abuse, reduced death rate points to OD reversal drug naloxone, not opioid substitute Suboxone

Consistent evidence – as the national “dose” of substitute opioid medical “fix” and “anti-addiction drug” buprenorphine has steadily and substantially increased – of a concurrently worsening, lethal epidemic – outlined in this post:

More Signs U.S. Medical Industry Magic Pill Approach to Opioid Crisis on Same Track as Decades-Old Failed French Experiment of Unrestricted Buprenorphine Prescriptions in Primary Care

Rampant, runaway diversion and abuse of the prescribed, addictive substitute opioids in France and the U.S., enough in France to fuel buprenorphine abuse epidemics in another country – described in this post:

The French Connection France’s Decades-Long Unrestricted Buprenorphine (Substitute Opioid) Campaign – Promoted as the “Fix” for U.S. Opioid Crisis – is Fueling Widespread Prescribed Opioid Diversion, Trade and Abuse

Lack of evidence to support the claim of efficacy for MAT/OST in reducing OD deaths or for other benefit, instead evidence for diverse harms – described in this post:

The Science: Following French Failure, Americans Get a Substitute Addictive Opioid as “Fix” for the Opioid Crisis, Marketed as Reducing Overdose Deaths Does It?

OST falsely constructed, branded as “treatment” thereby diverting public resources, attention, and policy away from existing evidence-based treatments for problem substance use including opioid use – described in this upcoming post:

Upcoming Post Opioid Epidemic: For Worsening Crisis French and U.S. Medical Systems Dispense Ongoing Addictive, Abused Substitute Opioids With No Evidence-Based Treatments, Predictable Outcomes
and these posts at A Critical Discourse:

Why Addiction Treatment Doesn’t Work

Why There is No Such Thing as “Addiction” – A Fabrication that Diverts Healthcare Resources to the Criminal Treatment Scams Driving Lethal Public Health Epidemics

Effective Substance Use Treatment Requires Ending All Funding and Treatment for “Addiction” – A Fabrication that Diverts Healthcare Resources to the Criminal Treatment Scams Driving Lethal Public Health Epidemics

Evidence falsifying and dismantling claims by the medical/harm-reduction industry that diverted substitute opioids are primarily or largely used in self-treatment by individuals motivated to stop high-risk opioid use, instead affirming misuse and abuse of diverted prescription opioids – described in this upcoming post:

Update, Opioid Crisis – Word from the Street: The Bupe Economy is About Abuse not Self-Treatment

New evidence below

Yearly increases in SAMHSA-reported reversals by use of OD-reversing naloxone account for any apparent decrease in U.S. opioid-related OD deaths, with no evidence for causative role for opioid substitution campaigns

First, to Review

Dayton header NYT

Across the U.S., buprenorphine population “dose” has been substantially increasing over past years and would have been increasingly available in any U.S. city to persons needing it as “treatment”, to stop or reduce high-risk opioid use – if not as prescribed in a medically-managed MAT program, then within the bupe diversion economy. We know that because it is so extensively and widely diverted, available illicitly to anyone wanting it. Diverted so widely and extensively that in France – model for the U.S. publicly-funded opioid crisis fix – “sub” diversion fuels illicit opioid economies in other countries.

While availability of the presumed medical fix was widely available either directly or black market, for years, overdose deaths continued to climb . . . and climb in Dayton, until abruptly and concurrently, as in Plumas County, there waw an intensive coordinated Naloxone campaign that included distribution, education, and training, was initiated. Then OD deaths dropped.

In Dayton fortuitous (or profit-driven) disappearance from the streets of carfentanil – a dangerous synthetic opioid driving many overdoses – cannot be ruled out as moderating OD deaths. But additional data and evaluation is needed to attribute a role for that change in the OD death outcomes:

Most determinative, were potentially lethal opioid-involved overdoses established and recorded as prevented by administration of Naloxone? If so, those reductions in OD deaths are attributable to Naloxone and cannot reasonably be attributed to changes in carfentanil presence.

Was fentanyl, also dangerous and increasing risk of lethal OD, still on the streets? And figuring in potentially lethal overdoses?

Did opioid-involved overdose decrease in frequency? Or remain largely unchanged, with OD deaths reduced? That would point to effects due to the Naloxone campaign, away from changes in risk of exposure to dangerous opioids on the street, away from “treatment” effects.

In Dayton, new traditional addiction treatment programs became operational the same year – 2018 – that lethal OD deaths decreased – seemingly too late to account for harm-reducing effects gained from successful extended engagement, change, and outcomes for individuals in programs – and there is no evidence, direct or other, to link the reduced deaths to effects of those programs. Those types of effects in any case would not be expected or predicted, because core elements of treatment as usual (TAU) in the U.S. for substance use problems predict at best no benefit, likely harm, one predictive and explanatory factor in continually worsening substance use epidemics.

shutterstock_empty chairs group meeting

Analysis and evaluation of effectiveness of responses in Dayton to the lethal and worsening opioid crisis must be, in any case, revisited and rethought in light of more comprehensive, recent local reporting:

1) opioid-related OD deaths trending back upward in the most recent months and

2) investigative work by the Dayton Daily News revealing – as associated with medical buprenorphine opioid substitution – widespread diversion for abuse; ineffective use of public health care funds constituting apparent Medicaid abuse, especially failure to provide the treatment part of medication assisted treatment (MAT); and criminal behavior by medical providers as commonly described in the U.S.

New: Yearly increases in use of OD-reversing naloxone account for any apparent decrease in U.S. OD deaths, with no evidence for causative role for opioid substitution campaigns

The National Institute for Drug Abuse (NIDA) has released data attributing in the U.S a gain in number of potentially lethal opioid overdoses reversed by use of Naloxone as increasing, over 2010 to 2014, from 10,171 to 26,463. The NIDA data, through 2014, is almost certainly an underestimate unless we assume that most reversals, including private, are reported and recorded, and incidence of reversals almost certainly has increased in the interval since 2014 as Naloxone programs have expanded, as in Dayton. At a rate of net gain in potentially lethal OD deaths stopped by use of Naloxone of 4,000 per year, almost certainly conservative, Naloxone appears to directly account for any apparent moderation of opioid related overdose deaths in national trend.

As in Plumas County and Dayton, nationally Naloxone can directly account for any and all changes in overdose deaths, and there is no effect remaining to attribute to claimed benefit from provision of substitute opioids.

That substitute opioid effect would not be predicted.

Because as discussed in detail in posts here at A Critical Discourse, with links to primary research and other material, while the direct, observable, recordable incidences of naloxone used to prevent a potentially lethal opioid-related overdose death allow clear conclusions to be drawn for the role of naloxone in any moderation of lethal overdose rates, attributing moderated OD deaths, or other gains, to OST/MAT requires evidence of some psychosocial benefits from use of OST/MAT that act to reduce high-risk opioid use and thereby rate of lethal overdose.

There are no such bodies of evidence, instead consistent evidence pointing to no benefit or harms, as established with links to primary sources: here, here, here, here, and here.

In Dayton Ohio and Plumas County, California opioid-related overdose deaths climbed . . . and climbed . . . with no observable response to traditional treatment or opioid substitute programs, no response to increasing dose accorss the U.S. of the medical fix for high risk opioid use – addictive substitute opioids.

Then dropped dramatically with the implementation of intensive campaigns to distribute and effectively use the OD death-reversing opioid antagonist naloxone, with no decreases in deaths left to attribute to OST.

Cincinnati, Ohio now joins those anomalous locales –

years of worsening opioid-related OD deaths, associated with increasing dose of the medical cure, until  abruptly with initiation of an intensive naloxone campaign, OD deaths decline.

That’s a pattern that belies claims that OST is effective and warrants massive investment of public healthcare funds, based on unsupported claims that OST reduces overdose deaths.

(from the Toledo Blade – December 26, 2018)

To Summarize

There has never existed evidence to credibly attribute decreases in opioid-related overdose deaths or other gains for individuals trapped in the opioid crisis to buprenorphine MAT interventions, versus other plausible explanations. Available evidence that is varied and congruent overwhelmingly points to lack of effects constituting the psychosocial, functional, behavioral, or recovery benefits required as mechanisms to support conclusions that buprenorphine provision provides benefit in reduced OD deaths or other measures.

Instead, evidence consistently points to prescribed buprenorphine as generating and involved in harms including: continued opioid dependence; diversion; abuse; child exposure; involvement in overdose and overdose deaths; involvement in emergency medical visits; involvement in criminal drug trafficking.

Cincinnati naloxone